$ILMN Breaks $220 After Q2 Beat and Guidance Raise
$Illumina(ILMN)$
$Illumina(ILMN) +2.89% Surges to 52-Week High, Clinical Sequencing Momentum Breaks $220 Resistance, $230 Target in Sight
Latest Close Data ILMN closed at $219.40 (+2.89%) on Aug 24, touching a fresh 52-week high of $220.43. After-hours strength at $219.11 confirms persistent bid. The stock now sits just 0.5% below that high, with YTD range of $88.00–$220.43.
Core Market Drivers RBC Capital's note that competitive fears are fading in clinical sequencing continues to fuel accumulation. Q2 beat (EPS $1.31 vs $1.23 est.; revenue $11.59B vs $11.30B est.) and raised FY guidance of $4.52–$4.62B keep fundamentals strong. Capital flow turned sharply positive with 5-day net inflow of $3,267.79M.
Technical Analysis Volume of 1.92M shares (VR 1.12) supports the breakout. MACD histogram flipped positive at +1.07 and expanded to +3.21, while DIF (5.25) has crossed above DEA (3.64) — a confirmed bullish crossover. RSI(6) at 81.0 and RSI(12) at 71.1 indicate overbought conditions, but KDJ J-value of 108.4 shows momentum still accelerating. Watch for short-term consolidation before continuation.
Key Price Levels
-
Primary Support: $213.24 (prior close / breakout retest zone)
-
Immediate Pivot: $219.76 (Aug 21 resistance, now flipped to support)
-
Strong Resistance: $220.43 (52-week high) → $230.00 (RBC target)
Valuation Perspective Forward PE of 41.0 is below the historical average of 65.1 and near the +1 Std.Dev level of 128.3, suggesting reasonable valuation relative to growth. P/S TTM of 7.37 and P/B of 11.67 reflect premium quality pricing, justified by 32.3% ROE.
Analyst Targets 19 analysts cover ILMN: 5 Strong Buy, 6 Buy, 8 Hold, 2 Underperform, 1 Sell. Average target $193.95 (below current price), but RBC's $230 high target aligns with the bullish technical breakout.
Weekly Outlook Expect a $213–$230 consolidation range. A daily close above $220.43 opens the path to $230; failure to hold $213.24 could trigger profit-taking toward $208.50 (today's low). Momentum favors continuation, but RSI overbought suggests a brief pause is healthy.
⚠️ Risk Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results. Always conduct your own research before trading.
$Illumina(ILMN) Options Strategy: Bull Call Spread
-
Underlying: ILMN (Illumina)
-
View: Cautiously bullish; breakout above $220 resistance, targeting $230
-
Strategy Type: Debit spread / directional long with defined risk
-
Option Contract Portfolio:
-
Buy 1x Sep 18, 2026 $220 Call @ $11.00 mid
-
Sell 1x Sep 18, 2026 $230 Call @ $7.40 mid
-
-
Max Gain & Loss:
-
Max Gain: $6.40 per share ($640 per spread)
-
Max Loss: $3.60 per share ($360 per spread)
-
-
Initial Cost/Debit: $3.60 net debit per share ($360 per spread)
🐯🪙 Share your choice and reasoning in the comments — thoughtful views may receive Tiger Coins!
Good allocation isn’t just about investing — it’s also about keeping everyday life organised.
Just like a well-balanced portfolio, the right organisation can make business trips, travel and workouts a little easier. The new Tiger Toiletry Bag features a dual-layer dry & wet separation design with plenty of space to keep your essentials neatly organised, wherever you go.
Redeem the new Tiger Toiletry Bag now in Tiger Coin Mall. https://laohu8.com/J/redeemGift?goodID=100538&type=delivery
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

